Lumida
/IART
⌘K
Integra Lifesciences Holdings Corp

Integra Lifesciences Holdings Corp

IART
$15.50USD↓-0.26%-0.04 today

MARKET CAP

1.2B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$15 – $16

52W RANGE

$9
$20

AI Summary

Stalk
Sell NowMedium

IART is in a Stage 4 distribution phase with a decisive Support Failure breaking below key $15.50 support. Price trades below the 9EMA, 20EMA, and 50DMA with continued downward follow-through and no signs of exhaustion despite extreme oversold readings. The medium-term bias is firmly bearish, and short-term conditions favor selling into any relief rallies toward the short EMAs or the former support zone. The long-term uptrend remains intact above the 200DMA but is overshadowed by near-term supply dominance.

  • ↑Compliance Master Plan boosts supply execution and operational stability.
  • ↑Q2 revenue $419M (+7% seq.); adjusted EPS $0.56 tops guidance.
  • ↓Gross margin fell ~350bps, with full-year margins down ~260bps.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a leader in the medical technology sector, focusing on surgical solutions and regenerative medicine with a particular emphasis on neurosurgery, spine surgery, and wound reconstruction. The company is currently undergoing a transformation to enhance operational compliance and quality management systems while maintaining a strong product pipeline. Integra's broad focus on innovation positions it well within the evolving healthcare landscape, catering to growing procedural needs and patient care standards.

Bull says

  • ↑Compliance Master Plan boosts supply execution and operational stability.
  • ↑Q2 revenue $419M (+7% seq.); adjusted EPS $0.56 tops guidance.
  • ↑Tissue reconstruction revenues $109M (+6.7% YoY) support market strength.
  • ↑Tariff tailwind adds ~$0.05 per share to earnings.
  • ↑Organic revenue growth guided at 0.8–3.3% for FY.
  • ↑High earnings yield, strong book-to-price, positive momentum factors.

Bear says

  • ↓Gross margin fell ~350bps, with full-year margins down ~260bps.
  • ↓Compliance execution remains incomplete, posing ongoing operational risk.
  • ↓Net debt $1.6B (4.1x leverage) limits financial flexibility.
  • ↓Product relaunch to recapture recalls spans multiple quarters.
  • ↓Profitability factors weak and analyst revisions trending negative.
  • ↓Negative dividend yield and smaller size heighten investor caution.

Investment themes with IART

Medical Devices↓ -0.50%

Devices and instruments for medical treatment

ISRG · ABT · SYK

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-15-2026neutral

Transcript signals

Bull points

  • I'm encouraged by the progress we're making in establishing the foundation for operational excellence and a culture of continuous improvement that will drive long-term performance consistency and reliability across our business.
  • we delivered global revenue of $415.6 million exceeding the high end of our guidance. Reported and organic revenue growth were both down slightly versus the prior year, which was expected and previously communicated during our Q1 earnings call. This was largely due to the impact of up-setting healthy mid-single-digit growth across the portfolio, which underscores continued demand for our differentiated products.
  • A standout this quarter was Integrate Skin. Through our manufacturing resiliency and yield improvement effort, we achieved the company's highest ever production levels in Q2 and expect to maintain normal revenue run rate through the rest of the year.

Bear points

  • We're also driving cost efficiencies to restore the earning power of the business and generate margin expansion, reinforcing our ability to deliver meaningful returns to our shareholders.
  • we have seen increased payer pressure over the last year, and it happens to be varied by geography as well.
  • we have seen increased payer pressure over the last year, and it happens to be varied by geography as well.
Read full transcript analysis ›